Maria Grazia Filippone
[email protected] | |
Telephone | 02-94375052 |
Location |
Building 13
Floor 1st Via Adamello 16, Milano |
Member of
I am a postdoc fellow in the Hormone-Related Cancers Research Unit, directed by Prof. S. Pece, in the Dept. of Experimental Oncology at IEO. My research interests lie in deciphering the molecular mechanisms contributing to breast cancer with the ultimate goal of developing new strategies for the personalized treatment of patients. My current project is focused on the pre-clinical validation of the Ser/Thr kinase, CDK12, as a biomarker in breast cancer.
I have a bachelor’s degree in Biotechnological Sciences and a master’s degree in Medical Biotechnologies from the University of Naples “Federico II”. I performed my PhD in Genetics and Molecular Medicine, in Dr. M. Zannini’s group at the Dept. of Cellular and Molecular Biology and Pathology “L. Califano”, University of Naples "Federico II". My thesis investigated the role of the Wnt4gene in thyroid cells and its regulation by the transcription factor Pax8. After my PhD, I was awarded an EMBO Short-Term Fellowship to study the Na+/I- symporter and the effect of 131I-therapy in ovarian cancer, in Dr. Nancy Carrasco’s lab at the Yale School of Medicine (CT, USA). I then returned to Dr. M. Zannini’s group to work on the identification of molecular targets and the development of inhibitors of miRNA, aptamers and siRNA, before joining Prof. P.P. Di Fiore’s group at IEO in 2015 as a postdoc to study the molecular mechanisms regulating the asymmetric partitioning of the cell fate determinant Numb in mammary stem cells.
Most Relevant Publications
-
Pax8 modulates the expression of Wnt4 that is necessary for the maintenance of the epithelial phenotype of thyroid cells
BMC Mol Biol, 2014
-
Pax8 has a critical role in epithelial cell survival and proliferation.
Cell Death Dis, 2013
-
Aberrant phosphorylation inactivates Numb in breast cancer causing expansion of the stem cell pool.
J Cell Biol, 2022
-
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.
Nat Commun, 2022